HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $16 price target.
June 28, 2024 | 3:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating on Esperion Therapeutics and maintained a $16 price target, indicating continued confidence in the company's stock.
The reiteration of a Buy rating and maintenance of a $16 price target by a reputable analyst suggests positive sentiment and potential upside for Esperion Therapeutics' stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100